Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms

Journal of Clinical Pharmacology

Volumn 54, Issue 5, 2014, Pages 495-502

  Suenaga, Mitsukuni ^a   Fuse, Nozomu ^b   Yamaguchi, Tatsuro ^c   Yamanaka, Yasuhiro ^d   Motomura, Shigeki ^e   Matsumoto, Hiroshi ^c   Hamamoto, Yasuo ^d   Mizunuma, Nobuyuki ^a   Doi, Toshihiko ^b   Hatake, Kiyohiko ^a   Iwasaki, Junko ^f   Ohtsu, Atsushi ^b  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d TOCHIGI CANCER CENTER   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

^f CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

bevacizumab; colorectal cancer; FOLFIRI; UGT1A1

Indexed keywords

BEVACIZUMAB; FIRTECAN; FIRTECAN GLUCURONIDE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; MONOCLONAL ANTIBODY; UGT1A1 ENZYME;

ADULT; AGED; ALLELE; ANOREXIA; AREA UNDER THE CURVE; BREAST ABSCESS; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSCIOUSNESS DISORDER; DIARRHEA; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM CANCER; DUODENUM ULCER; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERAMMONEMIA; HYPERTENSION; JAPANESE; KIDNEY DISEASE; LEUKOPENIA; LUNG EMBOLISM; MALE; MENSTRUATION DISORDER; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PROGRESSION FREE SURVIVAL; REVIEW; STOMACH CANCER; STOMACH ULCER; STOMATITIS; THROMBOSIS; TREATMENT RESPONSE; VASCULAR DISEASE; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DRUG INTERACTION; GENETICS; MIDDLE AGED; NAUSEA; NEUTROPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANOREXIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DRUG INTERACTIONS; FEMALE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; TREATMENT OUTCOME;

EID: 84898624778     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.246     Document Type: Review

References (23)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917.
2. National Cancer Center, Center for Cancer Control and Information Services. Cancer Statistics in Japan (2011). http://ganjoho.ncc.go.jp/public/ statistics/pub/update.html. Accessed July 20, 2013.
3. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21: 60-65.
4. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23: 3697-3705.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342. (Pubitemid 38702844)
6. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25: 1539-1544. (Pubitemid 46733080)
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: colon cancer version 3. 2012 http://www.nccn.org/professionals/physician-gls/ PDF/colon.pdf. Accessed July 20, 2013.
8. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K., Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991; 51: 4187-4191.
9. Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996; 56: 3752-3757. (Pubitemid 26272025)
10. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004; 22: 1382-1388. (Pubitemid 41103619)
11. Marcuello E, Altés A, Menoyo A, Del Rio E, Gõmez-Pardo M, Baiget M., UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer. 2004; 91: 678-682. (Pubitemid 39141623)
12. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ., Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994; 54: 3723-3725. (Pubitemid 24241187)
13. Kudoh S, Fukuoka M, Masuda N, et al. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res. 1995; 86: 406-413.
14. Han JY, Lim HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 2006; 24: 2237-2244.
15. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000; 60: 6921-6926. (Pubitemid 32059164)
16. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther. 2004; 75: 501-515. (Pubitemid 38746601)
17. Denlinger CS, Blanchard R, Xu L, et al. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009; 65: 97-105.
18. Beutler E, Gelbart T, Demina A., Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism ? Proc Natl Acad Sci USA. 1998; 95: 8170-8174. (Pubitemid 28326085)
19. Kaniwa N, Kurose K, Jinno H, et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American. Drug Metab Dispos. 2004; 33: 458-465. (Pubitemid 40279948)
20. RECIST (Response Evaluation Criteria In Solid Tumors) Version 1.1 update, criteria comparison tool (2009). http://www.recist.com/recist-comparative/01. html. Accessed July 21, 2013.
21. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v3.0 (2006). http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf. Accessed July 21, 2013.
22. Saito Y, Maekawa K, Ozawa S, Sawada J., Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in East Asians and their comparison with other ethnic populations. Curr Pharmacogenomics. 2007; 5: 49-78. (Pubitemid 46403580)
23. Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 2009; 77: 113-119.